Plant-based diet in hyperkalemic chronic kidney disease patients receiving sodium zirconium cyclosilicate: a feasibility clinical trial

被引:3
|
作者
Avesani, Carla Maria [1 ]
Heimburger, Olof [1 ]
Rubin, Charlotta [2 ]
Sallstrom, Torsten [3 ]
Faxen-Irving, Gerd [4 ]
Lindholm, Bengt [1 ]
Stenvinkel, Peter [1 ]
机构
[1] Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Renal Med, Baxter Novum, Solna, Sweden
[2] Karolinska Univ Hosp, Med Unit Clin Nutr, Stockholm, Sweden
[3] Nykoping Hosp, Dept Dietet, Nykoping, Sweden
[4] Karolinska Inst, Div Clin Geriatr, Dept Neurobiol Care Sci & Soc, Solna, Sweden
关键词
chronic kidney disease; dietary potassium; plant-based diet; hyperkalemia; potassium binders; HEMODIALYSIS-PATIENTS; METABOLIC-ACIDOSIS; LOWER RISK; CKD; MORTALITY; PATTERNS; FRUIT;
D O I
10.1016/j.ajcnut.2024.06.025
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background Plant-based diets (PBD) may induce hyperkalemia in chronic kidney disease (CKD) patients. Objectives We explored the safety and feasibility of PBD in hyperkalemic CKD patients receiving the potassium binder sodium zirconium cyclosilicate (SZC). Methods In the current 6-wk trial, 26 hyperkalemic patients with CKD stage 4-5 not on dialysis received a low-protein low-potassium diet plus SZC for 3 wk and then a PBD with high potassium content delivered as a weekly food basket while continuing SZC for subsequent 3 wk. Plasma potassium was monitored weekly and SZC was titrated to achieve normokalemia. The 24-h urine excretion of potassium and sodium, 24-h food records, dietary quality, nutritional status, Bristol stool scale, Quality of life (QoL), and renal treatment satisfaction were assessed at baseline (week 0), week 3, and week 6. Results Mean plasma potassium decreased from 5.5 to 4.4 mEq/L within 48-72 h after baseline, then rose to 4.7-5.0 mEq/L throughout the remaining study period following dose adjustments of SZC that matched the increased potassium intake of PBD from week 3 to week 6. Over the study period, 24-h urinary potassium excretion decreased from week 0 to week 3 and increased from week 3 to week 6. During the study, 58% of patients had fasting plasma potassium between 3.5 and 5.0 mEq/L and there was no episode of plasma potassium >6.5 mEq/L or <3.0 mEq/L during the study. P-carbon dioxide increased from baseline until week 6 (21 +/- 2 to 23 +/- 2 mEq/L; P = 0.002; mean +/- SD), whereas remaining laboratory values remained unchanged. Fiber intake, dietary quality, the domain physical functioning from QoL, and 1 question of renal treatment satisfaction improved, whereas stool type and frequency did not change after starting PBD. Conclusions PBD in hyperkalemia-prone CKD patients receiving SZC improved dietary quality and increased the intake of healthy foods, whereas plasma potassium concentration remained stable within normal values for most patients.
引用
收藏
页码:719 / 726
页数:8
相关论文
共 50 条
  • [1] Compared effectiveness of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on hyperkalemia in patients with chronic kidney disease
    Nakayama, Takashin
    Yamaguchi, Shintaro
    Hayashi, Kaori
    Uchiyama, Kiyotaka
    Tajima, Takaya
    Azegami, Tatsuhiko
    Morimoto, Kohkichi
    Yoshida, Tadashi
    Yoshino, Jun
    Monkawa, Toshiaki
    Kanda, Takeshi
    Itoh, Hiroshi
    FRONTIERS IN MEDICINE, 2023, 10
  • [2] Association between plant-based diet quality and chronic kidney disease in Australian adults
    Stanford, Jordan
    Stefoska-Needham, Anita
    Lambert, Kelly
    Batterham, Marijka J.
    Charlton, Karen
    PUBLIC HEALTH NUTRITION, 2024, 27 (01)
  • [3] Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent
    Rastogi, Anjay
    Hanna, Ramy M.
    Mkrttchyan, Anita
    Khalid, Maham
    Yaqoob, Sinan
    Shaffer, Kelly
    Dhawan, Puneet
    Nobakht, Niloofar
    Kamgar, Mohammad
    Goshtaseb, Ray
    Sarmosyan, Kristine
    Gnarini, Mariarosaria
    Wassef, Olivia
    Lerma, Edgar
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (09) : 1055 - 1064
  • [4] Cost-effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalemia in patients with chronic kidney disease or heart failure in Spain
    Alcazar-Arroyo, Roberto
    Crespo-Leiro, Maria G.
    Bover, Jordi
    Oliva, Juan
    Sequera-Mutiozabal, Miren
    Gradari, Simona
    Marinez-Lopez, Anisia
    Lopez-Chicheri, Blanca
    Vidal-Vilar, Neus
    Aceituno, Susana
    Cobo, Marta
    NEFROLOGIA, 2024, 44 (05): : 709 - 720
  • [5] Effects of Patiromer and Sodium Zirconium Cyclosilicate on Blood Pressure in Rats with Chronic Kidney Disease
    Li, Lingyun
    Budden, Jeff
    Quinn, Carol Moreno
    Bushinsky, David
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2024, 29
  • [6] Hyperkalemia and Plant-Based Diets in Chronic Kidney Disease
    Babich, John Sebastian
    Dupuis, Leonie
    Kalantar-Zadeh, Kamyar
    Joshi, Shivam
    ADVANCES IN KIDNEY DISEASE AND HEALTH, 2023, 30 (06): : 487 - 495
  • [7] Effect of Sodium Zirconium Cyclosilicate on Serum Potassium and Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease: Rationale and Design of the NEUTRALIZE Study
    Ash, Stephen R.
    Batlle, Daniel
    Kendrick, Jessica
    Oluwatosin, Yemisi
    Pottorf, William
    Brahmbhatt, Yasmin
    Guerrieri, Emily
    Fried, Linda
    NEPHRON, 2022, 146 (06) : 599 - 609
  • [8] Cost-effectiveness of sodium zirconium cyclosilicate for advanced chronic kidney patients in Singapore
    Chay, Junxing
    Choo, Jason C. J.
    Finkelstein, Eric A.
    NEPHROLOGY, 2024, 29 (05) : 278 - 287
  • [9] Ameliorating Chronic Kidney Disease Using a Whole Food Plant-Based Diet
    Adair, Kathleen E.
    Bowden, Rodney G.
    NUTRIENTS, 2020, 12 (04)
  • [10] Plant-based diets in patients with chronic kidney disease
    Wathanavasin, Wannasit
    Kittiskulnam, Piyawan
    Johansen, Kirsten L.
    ASIAN BIOMEDICINE, 2024, 18 (01) : 2 - 10